Jamal Nabhani, MD
Urology · Los Angeles, CANPI 1750658951
Payments from drug & device makers
What this record shows
Boston Scientific accounts for 70.1% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2021 at $1,208 and has fallen 95.7% since, to $52 in 2025. That places this record below the midpoint for urology clinicians in CA, where the typical reported total is $2,485.
Across 21 payments — averaging $100.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$1K
- Photocure Inc$189
- Procept Biorobotics Corporation$145
- AbbVie$62
- Sumitomo Pharma America, Inc.$44
- Tolmar, Inc.$42
- plus $149 from 6 others
What the payments were for
- Consulting fees$1,06350%
- Food & beverage$1,05050%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 5 | $1,481 |
| Photocure Inc | 2 | $189 |
| Procept Biorobotics Corporation | 1 | $145 |
| AbbVie | 2 | $62 |
| Sumitomo Pharma America, Inc. | 2 | $44 |
| Tolmar, Inc. | 2 | $42 |
| Innovation Technologies Inc | 1 | $37 |
| Teleflex LLC | 2 | $36 |
| AstraZeneca | 1 | $24 |
| Sagent Pharmaceuticals | 1 | $19 |
| Johnson & Johnson | 1 | $18 |
| Hollister Incorporated | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL - THERAPIES$1,063
- AMS AMBICOR$174
- Cysview$149
- AquaBeam Robotic System$145
How this compares
$2,113 in reported general payments places this provider in the 45th percentile of 1,324 urology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tolterodine Tartrate ErTolterodine Tartrate | 33 | $2,768 |
| Methenamine Hippurate | 28 | $1,761 |
| Tamsulosin Hcl | 130 | $1,164 |
| Potassium Citrate ErPotassium Citrate | 12 | $974 |
| Finasteride | 49 | $269 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 11 | $195 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 24 | $122 |
| Solifenacin Succinate | 12 | $80 |
| Ciprofloxacin Hcl | 16 | $54 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 14 | $45 |
| Cephalexin | 11 | $32 |
Paid to pharmacies, not to this prescriber.
Other urology in Los Angeles
- Arie BelldegrunLos Angeles$1.8M
- Mihir DesaiLos Angeles$1.5M
- Stuart HoldenLos Angeles$1.1M
- William AronsonLos Angeles$540K
- Amir LebastchiLos Angeles$478K
- Nazy ZomorodianLos Angeles$309K
- Jeffrey Loh-DoyleLos Angeles$308K
- Siamak DaneshmandLos Angeles$306K
- Karim ChamieLos Angeles$291K
- Brian ShuchLos Angeles$166K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.